Sébastien Iva is the new President of Fab'entech, a Lyon-based biotech founded in 2009 specializing in the development and production of polyclonal antibodies intended for the treatment of emerging infectious diseases and the development of bio-defense solutions.Its mission is to ensure its development and transformation, with the stated objective of becoming a key player in polyclonal antibodies.He took over from Bertrand Lépine, founder of Fab'entech, who became a member of the Supervisory Board.A graduate of the Ecole Supérieure de Commerce – training supplemented by a course at HEC and INSEAD -, Sébastien Iva has nearly 25 years of professional experience in the health sector.He began his career in marketing and sales at Sanofi headquarters in 1996, before working in Asia for several years.In 1999, he joined Stallergenes-Greer, a laboratory specializing in allergen immunotherapy – leader in its market and in full international expansion – as a member of the management team.It thus strongly contributes to the international development of activities.After 12 years with Stallergenes-Greer in various management positions, Sébastien successfully led the restructuring of the International Operations of Thuasne, a major player in the field of medical devices.More recently, he was the COO (Chief Operating Officer) of a Swiss start-up specializing in the diagnosis of neurological pathologies.His experience in start-ups, as in international groups, gives him assets to transform Fab'entech and accelerate the projects initiated in recent years.“I am delighted to take over the Presidency of Fab'entech at a pivotal moment in its history.We are simultaneously carrying out several major projects, in particular the development of a treatment against COVID-19 and the creation of a new industrial site in the Lyon region to produce quickly and on a large scale in France.We also have ambitious programs in the development of bio-defense solutions in collaboration with the Direction Générale de l'Armement (DGA).We are currently finalizing the first tranche of a new fundraiser to accelerate our ongoing programs.These sizeable projects will establish Fab'entech as a major player in the treatment of emerging infectious diseases and medical countermeasure solutions” concludes Sébastien Iva.Share the post "Sébastien Iva, new President of Fab'entech"Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative immuno-oncology treatments targeting G-protein-coupled receptors (GPCRs), has just announced a Series A fundraising of €39m (US $42m) led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and an existing investor, Seventure Partners.In its latest study, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reveals in particular significant disparities in access to new drugs for patients in Europe but also within a country.A 90% gap in patient access was found between Northern and Western European countries and Southern and Eastern European countries.BioWin, the health competitiveness cluster of the Walloon Region, has just announced the launch of Urgence Talents, a new initiative aimed at meeting the challenges posed by recruitment in the biotech and medtech industry in Belgium.For the first time, public and private players are joining forces to meet the specific and urgent needs of companies seeking to recruit talent in the biotechnology and health industry sectors.GeNeuro, a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), has announced that it has received authorization from the Swiss Health Authority (Swissmedic) to launch a phase II study evaluating temelimab in patients with severe post-COVID neuropsychiatric syndromes.Sanofi announced that the results of a pre-specified analysis of pooled data from the pivotal Phase III MELODY trial and Phase IIb trials of nirsevimab showed an efficacy (relative risk reduction compared to placebo) of 79.5 % (95 CI: 65.9 to 87.7; p<0.0001) against lower respiratory tract infections requiring medical management, such as bronchiolitis or pneumonia, caused by RSV in infants born in term or late premature at the start of their first season of RSV1 circulation.Biotech TheraVectys has just demonstrated the efficacy of its lentiviral vaccine candidate Lenti-COVID in animals, administered as a booster dose nasally, six months after the primary vaccination with a messenger RNA vaccine.Share the post “TheraVectys has developed the 1st intranasal Lenti-Covid vaccine candidate generating effective immunity” FacebookTwitterGoogle+E-mailNoxxon Pharma, a biotechnology company specializing in the development of improved cancer treatments targeting the tumor microenvironment (MET), has announced the appointment of two leading brain cancer experts to its Scientific Advisory Board (SAB).Every Monday, our free newsletter